|
|
Article: BrainStorm Cell Therapeutics' Consultant to Assist with Final Regulatory Preparations Towards Clinical Trials For ALS Patients Based on Stem Cells Treatment.
- Article from:
- Business Wire
- Article date:
- February 9, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK & PETACH TIKVAH, Israel -- BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell (ASC) technology, announced today that the company has retained the services of Bio Medical Research Design (BRD) headed by Dr. Moshe Neuman to consult BrainStorm's regulatory team in its preparations for clinical trials of ALS patients in Israel.
BrainStorm previously announced its plan to proceed to clinical trials for ALS disease in Israel and therefore engaged BRD to assist with the various final pre-clinical studies and stem cells production process that will help fulfill the relevant regulatory requirements.
BRD has a strong ...